To examine the different response trajectories of patients with Parkinson’s disease psychosis (PDP) treated with pimavanserin who share similar patient profiles in baseline characteristics.
Dashtipour et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: